TJX Companies Q4 Earnings Call Highlights

argenex Q4 Earnings Call Highlights

argenx (NASDAQ:ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, and its first year of annual operating profitability. Phase 3 ADAPT OCULUS hit primary endpoint in ocular MG Chief Medical Officer Luc Truyen said the company’s Phase 3 ADAPT OCULUS trial was designed as the first registrational study in ocular MG, enrolling patients with MGFA …

TJX Companies Q4 Earnings Call Highlights

TJX Companies (NYSE:TJX) reported fourth-quarter fiscal 2026 results that management said were “well above” expectations, citing broad-based comparable sales growth, improved margins, and continued customer traffic gains across most banners. Executives also outlined fiscal 2027 guidance calling for

Asure Software Q4 Earnings Call Highlights

Asure Software (NASDAQ:ASUR) executives told investors the company exited fiscal 2025 with accelerating organic growth, expanding profitability metrics, and early signs that its revamped client portal and artificial intelligence initiatives are improving cross-sell performance and operating efficiency. Revenue growth and improving organic trends Chairman and CEO Pat Goepel said full-year 2025 revenue rose 17% year […]

H2O America Q4 Earnings Call Highlights

H2O America (NASDAQ:HTO) executives used the company’s fourth-quarter call to highlight 2025 earnings near the top end of guidance, an expanded five-year capital plan, and progress on pending Texas acquisitions led by the proposed purchase of Quadvest. 2025 results and key drivers The company reported full-year 2025 diluted earnings per share (EPS) of $2.92 and […]